SCHEMBL2434873

SCHEMBL2434873

COC(=O)Cc1ccc2oc(Nc3ccccc3C)nc2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.58
RAB9A P51151 4/20 0.58
PKM P14618 2/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
TP53 P04637 1/20 0.58
KDM4E B2RXH2 1/20 0.53
ALDH1A1 P00352 1/20 0.53
MAPK1 P28482 1/20 0.53
MAPT P10636 2/20 0.48
USP2 O75604 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
C1R P00736 1/20 0.46
ITGA4 P13612 7/20 0.45
ITGB1 P05556 1/20 0.45
HPGD P15428 1/20 0.45
NFKB1 P19838 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45
IL6 P05231 1/20 0.44
STAT3 P40763 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2435619 0.91 ITGA4 (0.53) NPC1RAB9APKMSMN1; SMN2TP53
SCHEMBL2432748 0.89 NPC1 (0.60) NPC1RAB9APKMSMN1; SMN2TP53
SCHEMBL27596679 0.86 NPC1 (0.50) NPC1RAB9APKMSMN1; SMN2TP53
SCHEMBL6594613 0.85 IL6 (0.57) NPC1RAB9APKMSMN1; SMN2KDM4E
SCHEMBL2432858 0.82 NPC1 (0.43) NPC1RAB9APKMSMN1; SMN2TP53
SCHEMBL12327643 0.81 NPC1 (0.63) NPC1RAB9APKMSMN1; SMN2TP53
SCHEMBL31430617 0.81 NPC1 (0.53) NPC1RAB9APKMSMN1; SMN2KDM4E
SCHEMBL2429466 0.80 ITGA4 (0.56) NPC1RAB9APKMSMN1; SMN2TP53
SCHEMBL2434527 0.79 NPC1 (0.55) NPC1RAB9ASMN1; SMN2TP53KDM4E
SCHEMBL13356594 0.78 NPC1 (0.60) NPC1RAB9APKMSMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1346982-B1 VLA-4 INHIBITORS DAIICHI SEIYAKU CO (JP) 2011-09-14 EP disclosed
US-7157487-B2 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-01-02 US disclosed
US-7157487-B2 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-01-02 US disclosed
US-7157487-B2 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-01-02 US disclosed
US-20040110945-A1 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed
EP-1346982-A1 VLA-4 INHIBITORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-09-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110945-A1 Vla-4 inhibitors VCAM1, ITGA1, ITGB4 NPC1 1278/4885RAB9A 2530/4885PKM 4697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.